Comparative Pharmacology
Head-to-head clinical analysis: HALFLYTELY versus SUFLAVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALFLYTELY versus SUFLAVE.
HALFLYTELY vs SUFLAVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PEG 3350 is an osmotic agent that causes water retention in the colon, leading to bowel evacuation. Electrolytes (sodium sulfate, potassium chloride, magnesium sulfate, sodium bicarbonate) prevent significant electrolyte shifts.
SUFLAVE is a combination of sulfamethoxazole, a sulfonamide antibiotic, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits bacterial folic acid synthesis by blocking two consecutive steps: sulfamethoxazole competes with PABA to inhibit dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
Oral: 1 liter (provided as powder for reconstitution) administered at a rate of 240 mL every 10 minutes until rectal effluent is clear or 4 liters total is consumed. Typically given as split-dose: half the volume the evening before and half the morning of colonoscopy.
250 mg intravenously every 12 hours.
None Documented
None Documented
Not applicable; PEG 3350 is not significantly absorbed and does not have a systemic half-life. The colon transit time is approximately 1 hour after ingestion.
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in healthy adults; prolonged in renal impairment (up to 10 h in anuria)
Primarily fecal elimination of unabsorbed PEG 3350; negligible systemic absorption <0.06%. Electrolytes are excreted renally and fecally.
Renal: 70% unchanged; fecal/biliary: 20%; 10% metabolized to inactive glucuronide
Category C
Category C
Laxative
Laxative